Subject:
- Active Substance: Tofacitinib
- Name: Xeljanz®
- Therapeutic area: Ankylosing spondylitis
- Pharmaceutical company: Pfizer Pharma GmbH
Time table:
- Start: 15.12.2021
- Final decision by G-BA: 16.06.2022
Final decision:
- a1) Adult patients who have had an inadequate response to conventional therapy: No additional benefit proved
- a2) Adult patients who have had an inadequate response to, or intolerance to, prior biologic antirheumatic drug (bDMARD) therapy: No additional benefit proved